NEW YORK and BALTIMORE, March 22, 2018 /PRNewswire/ -- Deerfield Management announced today that it has committed $36 million of a $40 million Series A investment to advance Dracen Pharmaceuticals, Inc.'s novel immuno-metabolism pipeline. Dracen, a private company developing proprietary anti-cancer drugs discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), will use this financing to progress its programs into clinical trials for patients suffering from cancer.
Dracen will develop its platform of novel glutamine antagonists by building upon the immuno-metabolism effects demonstrated in preclinical cancer models. Immuno-metabolism is the convergence of cancer metabolism and immuno-oncology whereby agents disrupt the energy sources required to keep tumors alive while simultaneously inducing the patient's own immune system to fight cancer. Dracen intends to develop its glutamine antagonists both in single-agent settings as well as in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1.
"We are pleased to partner with Dracen and its founders from Johns Hopkins University," said Jonathan S. Leff, a Partner with Deerfield Management. "We see great potential for Dracen's approach to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies."
"We are excited to partner with Deerfield to advance our immuno-metabolism pipeline" remarked Thomas M. Estok, Chief Executive Officer of Dracen Pharmaceuticals. "Deerfield's engagement in our efforts helps bring us closer to an important potential step forward in the treatment of cancer."
About Dracen Pharmaceuticals
Dracen Pharmaceuticals, Inc. is a privately-funded biotech company developing proprietary glutamine antagonists discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague). Dracen was founded by Johns Hopkins University professors Barbara Slusher, MAS/PhD; Jonathan Powell, MD/PhD; and Rana Rais, PhD; together with their IOCB Prague collaborator Pavel Majer, PhD to develop the novel glutamine antagonists for the treatment of cancers as well as autoimmune and inflammatory diseases.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.
For more information, please visit www.deerfield.com
Deerfield Management Company
Karen Heidelberger, 212-551-1600
SOURCE Deerfield Management Company